menu
    • menu
    [{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Megapharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Megapharm","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Megapharm"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Tetris Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Tetris Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Tetris Pharma"},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tetris Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tetris Pharma \/ Arecor Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Tetris Pharma \/ Arecor Therapeutics"},{"orgOrder":0,"company":"AmideBio","sponsor":"NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"Glucagon","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmideBio \/ NIDDK","highestDevelopmentStatusID":"4","companyTruncated":"AmideBio \/ NIDDK"},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tetris Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tetris Pharma \/ Arecor","highestDevelopmentStatusID":"12","companyTruncated":"Tetris Pharma \/ Arecor"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":1.0800000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.0800000000000001,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":1.0800000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.0800000000000001,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Private Placement","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.29999999999999999,"dosageForm":"Powder","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Beta Bionics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Beta Bionics","highestDevelopmentStatusID":"4","companyTruncated":"Xeris Pharmaceuticals \/ Beta Bionics"},{"orgOrder":0,"company":"Abvance Therapeutics","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Insulin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abvance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abvance Therapeutics \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"14","companyTruncated":"Abvance Therapeutics \/ Helmsley Charitable Trust"}]

    Find Clinical Drug Pipeline Developments & Deals for Glucagon

    Menu

    Glucagon

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Abvance Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Abvance Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin,Glucagon

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Helmsley Charitable Trust

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Abvance Gets $3.9M Investment from Helmsley Trust For Insulin-Glucagon Drug

                            Details : The funding will support the pre-clinical development of ABV100, the Company’s initial proprietary insulin-glucagon combination candidate developing to treat diabetes.

                            Brand Name : ABV100

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : Insulin,Glucagon

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Helmsley Charitable Trust

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xeris Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Xeris Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Beta Bionics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LifeArc Makes Investment to Support Drug Discovery in Sub-Saharan Africa

                            Details : The collaboration aims for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            May 06, 2024

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Beta Bionics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amphastar Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Amphastar Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Undisclosed

                            Deal Size : $300.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes

                            Details : Amphastar intends to use the proceeds for the payment of milestone payments in connection with the acquisition of Baqsimi (glucagon) nasal powder, used to treat very low blood sugar (severe hypoglycemia) in people with diabetes ages 4 years and above.

                            Brand Name : Baqsimi

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 11, 2023

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Undisclosed

                            Deal Size : $300.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eli Lilly

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Amphastar Pharmaceuticals

                            Deal Size : $1,075.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly

                            Details : Through the divestment, Amphastar will continue Lilly's mission to help more people benefit from Baqsimi (glucagon), the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.

                            Brand Name : Baqsimi

                            Molecule Type : Peptide

                            Upfront Cash : $625.0 million

                            June 30, 2023

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Amphastar Pharmaceuticals

                            Deal Size : $1,075.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eli Lilly

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Amphastar Pharmaceuticals

                            Deal Size : $1,075.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Lilly to Divest BAQSIMI to Amphastar

                            Details : Through the divestment, Amphastar will continue Lilly's mission to help more people benefit from Baqsimi (glucagon), the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.

                            Brand Name : Baqsimi

                            Molecule Type : Peptide

                            Upfront Cash : $625.0 million

                            April 24, 2023

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Amphastar Pharmaceuticals

                            Deal Size : $1,075.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Xeris Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Xeris Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations

                            Details : Gvoke (glucagon) increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver.

                            Brand Name : Gvoke

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            April 18, 2023

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tetris Pharma

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tetris Pharma

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Arecor

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Tetris Pharma Signs Service Agreement With Syneos Health

                            Details : Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycaemia.

                            Brand Name : Ogluo

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            December 12, 2022

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Arecor

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AmideBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            AmideBio

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : NIDDK

                            Deal Size : $2.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            AmideBio Awarded SBIR Phase IIB Grant to Support Pre-Clinical Development of its Long-Acting Stable Glucagon A...

                            Details : This two-year grant will allow AmideBio to select a long-acting soluble stable glucagon candidate and do the necessary work to support the filing of an Investigational New Drug (IND) application with the FDA at the end of the grant period.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 04, 2022

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : NIDDK

                            Deal Size : $2.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tetris Pharma

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tetris Pharma

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Arecor

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Xeris’ Commercialization Partner for Ogluo, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics

                            Details : Under the terms of the proposed acquisition, Arecor Therapeutics has agreed to acquire Tetris Pharma and will continue to commercialize Ogluo in the UK and EEA. Gvoke® (US) /Ogluo® (EU), the first prescription, ready-to-use, pre-mixed, pre-measured glu...

                            Brand Name : Ogluo

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            August 01, 2022

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Arecor

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Xeris Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Xeris Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Tetris Pharma

                            Deal Size : $71.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Xeris Pharmaceuticals Ink License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in ...

                            Details : Under the terms of the applicable agreements, Xeris will be responsible for Gvoke® PFS and Gvoke HypoPen® (glucagon injection) supply and Tetris will be responsible for the commercialization of Ogluo in the Territory.

                            Brand Name : Ogluo

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            July 19, 2021

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Tetris Pharma

                            Deal Size : $71.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth